11 November 2022 in Frontiers in Oncology
Introduction: Imaging is integral part of cervical cancer management. Currently, MRI is used for staging, follow up and image guided adaptive brachytherapy. The ongoing IQ-EMBRACE sub-study is evaluating the use of MRI for functional imaging to aid in the assessment of hypoxia, metabolism, hemodynamics and tissue structure. This study reviews the current and potential future utilization of functional MRI imaging in diagnosis and management of cervical cancer.Methods: We searched PubMed for articles characterizing the uses of functional MRI (fMRI) for cervical cancer. The current literature regarding these techniques in diagnosis and outcomes for cervical cancer were then reviewed.Results: The most used fMRI techniques identified for use in cervical cancer include diffusion weighted imaging (DWI) and dynamic contrast enhancement (DCE). DCE-MRI indirectly reflects tumor perfusion and hypoxia. This has been utilized to either characterize a functional risk volume of tumor with low perfusion or to characterize at-risk tumor voxels by analyzing signal intensity both pre-treatment and during treatment. DCE imaging in these situations has been associated with local control and disease-free survival and may have predictive/prognostic significance, however this has not yet been clinically validated. DWI allows for creation of ADC maps, that assists with diagnosis of local malignancy or nodal disease with high sensitivity and specificity. DWI findings have also been correlated with local control and overall survival in patients with an incomplete response after definitive chemoradiotherapy and thus may assist with post-treatment follow up. Other imaging techniques used in some instances are MR-spectroscopy and perfusion weighted imaging. T2-weighted imaging remains the standard technique used for diagnosis and radiation treatment planning. In many instances, it is unclear what additional information functional-MRI techniques provide compared to standard MRI imaging.Conclusions: Functional MRI provides potential for improved diagnosis, prediction of treatment response and prognostication in cervical cancer. Specific sequences such as DCE, DWI and ADC need to be validated in a large prospective setting prior to widespread use. The ongoing IQ-EMBRACE study will provide important clinical information regarding these imaging modalities.
31 March 2022 in Radiation Oncology Journal
Purpose: Meningiomas are tumors originating from arachnoid cap cells on the surface of the brain or spinal cord. Treatment differs by grade but can consist of observation, surgery, radiation therapy or both. We utilized the National Cancer Database (NCDB) to compare trends in the use stereotactic radiosurgery (SRS) and external beam radiation therapy (EBRT) in the management of meningioma. Materials and Methods: We queried the NCDB from 2004–2015 for meningioma patients (grade 1–3) treated with radiation therapy, either SRS or EBRT. Multivariable logistic regression was used to identify predictors of each treatment and to generate a propensity score. Propensity adjusted Kaplan-Meier survival curve analysis and multivariable Cox hazards ratios were used to identify predictors of survival. Results: We identified 5,406 patients with meningioma meeting above criteria with 45%, 44%, and 11% having World Health Organization (WHO) grade 1, 2, and 3 disease, respectively. Median follow up was 43 months. Predictors for SRS were grade 1 disease, distance from treatment facility, and histology. The only predictor of EBRT was grade 3 disease. Treatment year, histology, race and female sex were associated with improved survival. Five- and 10-year survival rates were 89.2% versus 72.6% (p < 0.0001) and 80.3% versus 61.4% (p = 0.29) for SRS and EBRT respectively. After propensity matching 226 pairs were generated. For SRS, 5-year survival was not significantly improved at 88.2% compared with EBRT (p = 0.056).Conclusion: In the present analysis, predictors of SRS utilization in management of meningioma include WHO grade 1 disease, distance from treatment facility and histology whereas conventional EBRT utilization was associated with grade 2 and 3 disease. Future studies need to be performed in order to optimize management of atypical and malignant meningioma.
23 September 2023 in Brachytherapy
20 February 2022 in Journal of Clinical Oncology
419 Background: Spermatic cord sarcomas are a rare entity with management consisting of radical orchiectomy and the value of adjuvant radiation being unclear, as the literature consists of heterogeneous case series spanning multiple decades with limited numbers of patients. Methods: The National Cancer Data Base was queried for men who underwent orchiectomy for spermatic cord sarcomas between 2004 and 2018 with known surgical margin status. Kaplan-Meier with log-rank test and Cox proportional hazards tests were utilized for overall survival (OS) calculations. Associations were determined with bivariate regression analysis. Results: A total of 912 men were identified who met inclusion criteria. Six hundred seventeen (67.7%) had liposarcomas (LS) while 32.3% had non-lipsarcomatous (NLS) histologies. 5/10-year OS for men with LS was 85.1%/67.4% and 74.1%/58.4% for NLS, respectively (p < 0.001). 238 (26.1%) men were treated with adjuvant radiation therapy with similar distributions between LS and NLS. Utilization of radiation was significantly associated with moderate-poorly differentiated histology (HR 3.228 [95%CI 2.241-4.649] p < 0.001), radical orchiectomy (HR 1.477 [1.062-2.054] p = 0.020), positive surgical margins (HR 1.826 [95%CI 1.257-2.652] p = 0.002), but not histologic subtype or tumor size. There was no difference in OS for LS nor NLS with respect to the application of adjuvant radiation, but in men with moderately-poorly differentiated LS treated with adjuvant radiation, 5-year OS was 86.8% vs. 68.6% (p = 0.148). In men with well-differentiated LS, 5-year OS was 93.6% with XRT vs 89.5% (p = 0.623). Adjuvant XRT did not impact OS in men with positive surgical margins, nor did it have an impact on OS for NLS regardless of disease grade or margins. Conclusions: Adjuvant radiation therapy is utilized for approximately one quarter of men diagnosed with spermatic cord sarcomas. XRT may impact OS for men with moderately-poorly differentiated liposarcomas; further research with patient-level data is required.